|
|
(2 intermediate revisions not shown.) |
Line 1: |
Line 1: |
| | | |
| ==Crystal structure of acetylcholinesterase in complex with RVX== | | ==Crystal structure of acetylcholinesterase in complex with RVX== |
- | <StructureSection load='3zlt' size='340' side='right' caption='[[3zlt]], [[Resolution|resolution]] 2.60Å' scene=''> | + | <StructureSection load='3zlt' size='340' side='right'caption='[[3zlt]], [[Resolution|resolution]] 2.60Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[3zlt]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ZLT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ZLT FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[3zlt]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ZLT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3ZLT FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PE4:2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL'>PE4</scene>, <scene name='pdbligand=PG0:2-(2-METHOXYETHOXY)ETHANOL'>PG0</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.6Å</td></tr> |
- | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=RVX:O-[METHYL(2-METHYLPROPOXY)PHOSPHORYL]-L-SERINE'>RVX</scene></td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PE4:2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL'>PE4</scene>, <scene name='pdbligand=PG0:2-(2-METHOXYETHOXY)ETHANOL'>PG0</scene>, <scene name='pdbligand=RVX:O-[METHYL(2-METHYLPROPOXY)PHOSPHORYL]-L-SERINE'>RVX</scene></td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3zlu|3zlu]], [[3zlv|3zlv]]</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3zlt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3zlt OCA], [https://pdbe.org/3zlt PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3zlt RCSB], [https://www.ebi.ac.uk/pdbsum/3zlt PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3zlt ProSAT]</span></td></tr> |
- | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Acetylcholinesterase Acetylcholinesterase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.1.1.7 3.1.1.7] </span></td></tr>
| + | |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3zlt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3zlt OCA], [http://pdbe.org/3zlt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3zlt RCSB], [http://www.ebi.ac.uk/pdbsum/3zlt PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3zlt ProSAT]</span></td></tr> | + | |
| </table> | | </table> |
| == Function == | | == Function == |
- | [[http://www.uniprot.org/uniprot/ACES_MOUSE ACES_MOUSE]] Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. | + | [https://www.uniprot.org/uniprot/ACES_MOUSE ACES_MOUSE] Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 23: |
Line 21: |
| | | |
| ==See Also== | | ==See Also== |
- | *[[Acetylcholinesterase|Acetylcholinesterase]] | + | *[[Acetylcholinesterase 3D structures|Acetylcholinesterase 3D structures]] |
- | *[[3D structures of acetylcholinesterase|3D structures of acetylcholinesterase]]
| + | |
| == References == | | == References == |
| <references/> | | <references/> |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Acetylcholinesterase]] | + | [[Category: Large Structures]] |
- | [[Category: Lk3 transgenic mice]] | + | [[Category: Mus musculus]] |
- | [[Category: Akfur, C]] | + | [[Category: Akfur C]] |
- | [[Category: Andersson, P O]] | + | [[Category: Andersson PO]] |
- | [[Category: Artursson, E]] | + | [[Category: Artursson E]] |
- | [[Category: Borjegren, S]] | + | [[Category: Borjegren S]] |
- | [[Category: Ekstrom, F]] | + | [[Category: Ekstrom F]] |
- | [[Category: Linusson, A]] | + | [[Category: Linusson A]] |
- | [[Category: Cyclosarin]]
| + | |
- | [[Category: Ga]]
| + | |
- | [[Category: Gf]]
| + | |
- | [[Category: Hi-6]]
| + | |
- | [[Category: Hydrolase]]
| + | |
- | [[Category: Oxime]]
| + | |
- | [[Category: Russian vx]]
| + | |
- | [[Category: Tabun]]
| + | |
| Structural highlights
Function
ACES_MOUSE Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft.
Publication Abstract from PubMed
Nerve agents such as tabun, cyclosarin and Russian VX inhibit the essential enzyme acetylcholinesterase (AChE) by organophosphorylating the catalytic serine residue. Nucleophiles, such as oximes, are used as antidotes as they can reactivate and restore the function of the inhibited enzyme. The oxime HI-6 shows a notably low activity on tabun adducts but can effectively reactivate adducts of cyclosarin and Russian VX. To examine the structural basis for the pronounced substrate specificity of HI-6, we determined the binary crystal structures of Mus musculus AChE (mAChE) conjugated by cyclosarin and Russian VX and found a conformational mobility of the side chains of Phe338 and His447. The interaction between HI-6 and tabun-adducts of AChE were subsequently investigated using a combination of time resolved fluorescence spectroscopy and X-ray crystallography. Our findings show that HI-6 binds to tabun inhibited Homo sapiens AChE (hAChE) with an IC50 value of 300muM and suggest that the reactive nucleophilic moiety of HI-6 is excluded from the phosphorus atom of tabun. We propose that a conformational mobility of the side-chains of Phe338 and His447 is a common feature in nerve-agent adducts of AChE. We also suggest that the conformational mobility allow HI-6 to reactivate conjugates of cyclosarin and Russian VX while a reduced mobility in tabun conjugated AChE results in steric hindrance that prevents efficient reactivation.
Catalytic-site conformational equilibrium in nerve-agent adducts of acetylcholinesterase: Possible implications for the HI-6 antidote substrate specificity.,Artursson E, Andersson PO, Akfur C, Linusson A, Borjegren S, Ekstrom F Biochem Pharmacol. 2013 Jan 29. pii: S0006-2952(13)00053-1. doi:, 10.1016/j.bcp.2013.01.016. PMID:23376121[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Artursson E, Andersson PO, Akfur C, Linusson A, Borjegren S, Ekstrom F. Catalytic-site conformational equilibrium in nerve-agent adducts of acetylcholinesterase: Possible implications for the HI-6 antidote substrate specificity. Biochem Pharmacol. 2013 Jan 29. pii: S0006-2952(13)00053-1. doi:, 10.1016/j.bcp.2013.01.016. PMID:23376121 doi:10.1016/j.bcp.2013.01.016
|